These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 20123700)

  • 21. The relevance of persisters in tuberculosis drug discovery.
    Mandal S; Njikan S; Kumar A; Early JV; Parish T
    Microbiology (Reading); 2019 May; 165(5):492-499. PubMed ID: 30775961
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structural genomics approach to drug discovery for Mycobacterium tuberculosis.
    Ioerger TR; Sacchettini JC
    Curr Opin Microbiol; 2009 Jun; 12(3):318-25. PubMed ID: 19481971
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oxidative Phosphorylation as a Target Space for Tuberculosis: Success, Caution, and Future Directions.
    Cook GM; Hards K; Dunn E; Heikal A; Nakatani Y; Greening C; Crick DC; Fontes FL; Pethe K; Hasenoehrl E; Berney M
    Microbiol Spectr; 2017 Jun; 5(3):. PubMed ID: 28597820
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Developing pyrrole-derived antimycobacterial agents: a rational lead optimization approach.
    Biava M; Porretta GC; Poce G; Battilocchio C; Alfonso S; de Logu A; Manetti F; Botta M
    ChemMedChem; 2011 Apr; 6(4):593-9. PubMed ID: 21341373
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The achievements of the fundamental sciences and new approaches in the chemotherapy of tuberculosis].
    Egorov AM
    Probl Tuberk; 2000; (5):11-5. PubMed ID: 11077844
    [No Abstract]   [Full Text] [Related]  

  • 26. Leads for antitubercular compounds from kinase inhibitor library screens.
    Magnet S; Hartkoorn RC; Székely R; Pató J; Triccas JA; Schneider P; Szántai-Kis C; Orfi L; Chambon M; Banfi D; Bueno M; Turcatti G; Kéri G; Cole ST
    Tuberculosis (Edinb); 2010 Nov; 90(6):354-60. PubMed ID: 20934382
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Meropenem-clavulanate: a new strategy for the treatment of tuberculosis?
    Holzgrabe U
    ChemMedChem; 2009 Jul; 4(7):1051-3. PubMed ID: 19462395
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Mechanism of action "in vitro" and "in vivo" of antitubercular drugs].
    Gialdroni-Grassi G
    G Ital Chemioter; 1966; 13(1):11-26. PubMed ID: 4967319
    [No Abstract]   [Full Text] [Related]  

  • 29. Could Killing Bacterial Subpopulations Hit Tuberculosis out of the Park?
    Baranowski C; Rubin EJ
    J Med Chem; 2016 Jul; 59(13):6025-6. PubMed ID: 27322073
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Guanosine triphosphatases as novel therapeutic targets in tuberculosis.
    Rajni ; Meena LS
    Int J Infect Dis; 2010 Aug; 14(8):e682-7. PubMed ID: 20207570
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Physiological role and potential clinical interest of mycobacterial pigments.
    Robledo JA; Murillo AM; Rouzaud F
    IUBMB Life; 2011 Feb; 63(2):71-8. PubMed ID: 21360635
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structural and functional studies of mycobacterial IspD enzymes.
    Björkelid C; Bergfors T; Henriksson LM; Stern AL; Unge T; Mowbray SL; Jones TA
    Acta Crystallogr D Biol Crystallogr; 2011 May; 67(Pt 5):403-14. PubMed ID: 21543842
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification and validation of novel drug targets in Mycobacterium tuberculosis.
    Singh V; Mizrahi V
    Drug Discov Today; 2017 Mar; 22(3):503-509. PubMed ID: 27649943
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antituberculars which target decaprenylphosphoryl-β-D-ribofuranose 2'-oxidase DprE1: state of art.
    Buroni S; Pasca MR; de Jesus Lopes Ribeiro AL; Degiacomi G; Molteni E; Riccardi G
    Appl Microbiol Biotechnol; 2012 May; 94(4):907-16. PubMed ID: 22526781
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug resistance and fitness in Mycobacterium tuberculosis infection.
    Bottger EC; Pletschette M; Andersson D
    J Infect Dis; 2005 Mar; 191(5):823-4; author reply 824. PubMed ID: 15688309
    [No Abstract]   [Full Text] [Related]  

  • 36. The future for early-stage tuberculosis drug discovery.
    Zuniga ES; Early J; Parish T
    Future Microbiol; 2015; 10(2):217-29. PubMed ID: 25689534
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Molecular-genetic method of identification of drug-resistant Mycobacterium tuberculosis].
    Dubileĭ SA; Ignatova AN; Shemiakin IG
    Mol Gen Mikrobiol Virusol; 2005; (1):3-7. PubMed ID: 15790026
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Abnormalities of behavior in vitro of mycobacteria isolated from patients with tuberculosis].
    Cappellato M; Narpozzi A; Pastega G; Torresini G
    G Mal Infett Parassit; 1969 Jan; 21(1):49-75. PubMed ID: 4977162
    [No Abstract]   [Full Text] [Related]  

  • 39. More than cholesterol catabolism: regulatory vulnerabilities in Mycobacterium tuberculosis.
    Bonds AC; Sampson NS
    Curr Opin Chem Biol; 2018 Jun; 44():39-46. PubMed ID: 29906645
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Microbiology. An antibiotic mimics immunity.
    Nathan C
    Science; 2008 Nov; 322(5906):1337-8. PubMed ID: 19039126
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.